Nemucore Medical Innovations, Inc. Announces Election of Independent Director

WORCESTER, Mass. - June 8, 2015 - PRLog -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multi-drug resistant cancers, today announced the election of James B. Farinholt Jr. to Nemucore’s Board of Directors.

“We are extremely pleased to welcome Jim to our Board of Directors as an independent director. He shares our vision for building a patient-centric, sustainable biopharmaceutical organization,” said Dr. Timothy P. Coleman, Nemucore’s President and CEO. “Jim has an extensive track record in several segments of the life science industry and brings a depth of knowledge and experience in corporate governance that will be a significant resource for Nemucore as it transitions into a clinical development company.”

Mr. Farinholt has had an extensive career in both the private and public sectors of finance and investments. Most recently he served as a founding partner at Tall Oaks Capital Partners, a regional venture capital fund focused on early stage information technology and life sciences companies in the mid-Atlantic U.S. During the 1990s, he directed numerous business development activities at Virginia Commonwealth University where he served both as Rector and later as Assistant to the President for economic development. In conjunction with his promotion of the commercialization of scientific discoveries at the University, he initiated and oversaw several start-ups; and among them was Allos Therapeutics, Inc. which he co-founded and that went public in March 2000.

His earlier years in finance included roles as an executive officer in investment banking for small and medium-sized businesses at J. P. Morgan Chase in New York and Wheat First Union and Galleher & Company in Richmond, Virginia. Among the many companies for whom he managed their public offerings was Owens & Minor, Inc. the largest distributor of medical & surgical supplies in the U.S. Jim was appointed the company’s first independent director where he served on the Executive Committee as well as compensation, finance and strategic planning committees for the maximum term allowed under the company’s corporate policies.

About Nemucore Medical Innovations, Inc.

Nemucore Medical Innovations, Inc. is a privately held biopharmaceutical clinical-stage oncology company developing innovative therapeutics, with a focus on treating multi-drug resistant cancers. Nemucore's most advanced product NMI-900, a "Best-In-Class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late 2015. Two additional therapeutics are anticipated to begin clinical trials in 2016 targeting further oncology indications, including breast cancer.  For more information visit our website Nemucore.com (http://www.nemucore.com)

Forward Looking Statement

This press release makes forward-looking statements regarding future events and our future performance about the Company’s strategy, future plans and prospects, including statements regarding the development of the Company’s therapeutic programs, the timeline for clinical development and regulatory approval of the Company’s compounds, the structure of the Company’s planned clinical trials, the Company’s rights to develop or commercialize its products, the Company’s obligations to make milestone payments and royalties and the ability of the Company to finance contemplated development activities. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “proposed,” and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward-looking statements. Applicable risks and uncertainties include the risks that the preclinical testing of the Company’s compounds may not be predictive of the success of later clinical trials, that the Company may be unable to successfully complete the clinical development of its products, that the development of the Company’s products may take longer or cost more than planned, and that the Company’s products may not receive regulatory approval or become commercially successful products. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. More information about the risks and uncertainties faced by Nemucore Medical Innovations, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Nemucore Medical Innovations, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.